Drug Profile
Anti-CD20-anti-Fc alpha RI bispecific monoclonal antibody
Alternative Names: Bispecific monoclonal antibody anti-CD20-anti-Fc alpha RI-Medarex-TenovusLatest Information Update: 29 Aug 2002
Price :
$50
*
At a glance
- Originator Medarex; Nonindustrial source; Tenovus
- Developer Medarex
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action CD20 antigen inhibitors; Fc receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 29 Apr 1999 New profile
- 29 Apr 1999 Preclinical development for Cancer in USA (Unknown route)